References
- Baugh DK, Pine PL, Blackwell S et al. Medicaid prescription drug spending in the 1990s: a decade of change. Health Care Financ. Rev.25(3), 5–23 (2004).
- Young D. New Florida law restricts drugs for Medicaid. Am. J. Health-Syst. Pharm.58(8), 1477–1482 (2001).
- USC§ 1396r-8(d)(4)(C).
- Muirhead G. List Hissed. Georgia draws heavy flak for ‘preferred’ drug program. Drug Topics141, 40 (1997).
- Ung D, Robins L, Kenny G. Two Supreme Court actions will likely spur more states to implement and expand drug discount programs. Drug Benefit Trends15(9), 24–26 (2003).
- Lichtenberg F. The effect of access restrictions on the vintage of drugs used by Medicaid enrollees. Am. J. Manag. Care11(1) SP7–SP13 (2005).
- Lichtenberg F. The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997 to 2003. Pharmacoeconomics24(3), 5–25 (2006).
- Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics24(3), 65–78 (2006).
- Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am. J. Manag. Care11(1), SP7–SP13 (2005).
- Murawski MM, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. Am. J. Manag. Care11(1), SP35–SP42 (2005).
- Ketcham JD, Epstein AJ. Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives? Pharmacoeconomics24(3), 27–40 (2006).
- Abdelgawad T, Egbuonu-Davis L. Preferred drug lists and Medicaid prescriptions. Pharmacoeconomics24(3) 55–63 (2006).
- Wang YR, Pauly MV, Lin YA. Impact of Maine’s Medicaid drug formulary change on non-Medicaid markets; spillover effects of a restrictive drug formulary Am. J. Manag. Care9, 686–696 (2003).
- Wang YR, Pauly MV. Spillover effects of restrictive drug formularies on physician prescribing behavior: evidence from Medicaid journal of economic and management strategy. 14(3), 755–773 (2005).
- Wang YR. Spillover effects of restrictive drug formularies in the statin class: a descriptive study of the Medicaid preferred drug list in Texas. Manag. Care Interface19(11), 32–34 (2006).
- Virabhak S, Shinogle JA. Physician’s prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am. J. Manag. Care11(1) SP14–SP20 (2005).
- Headen AE, Masia NA, Axelsen KJ. Effects of Medicaid access restrictions on statin utilization for patients treated by physicians practicing in poor and minority neighborhoods. Pharmacoeconomics24(Suppl. 3), 41–53 (2006).
- Headen AE, Masia NA. Exploring the potential link between Medicaid access restrictions, physician location, and health disparities. Am. J. Manag. Care11(1), SP21–SP26 (2005).
- Hinkel N. Learning the list. The preferred drug list and how it works. J. Ark. Med. Soc.101(6), 168–170 (2004).
- Neumann PJ, Lin P, Greenberg D et al. Do formulary policies reflect evidence of value? Am. J. Manag. Care12(1), 30–36 (2006).
Websites
- Medicaid prescription drug program savings through the use of preferred drug lists (PDLs) Click here.
- Ohio’s Medicaid cost-containment strategies, quarterly report to the Ohio General Assembly, November, 2003. Ohio Department of Job and Family Services http://jfs.ohio.gov/oleg/medcostc.pdf
- Evaluation of the Indiana Medicaid preferred drug list (PDL) Program. Report 1 www.in.gov/legislative/igareports/agency/reports/FSSA14.pdf
- Evaluation of the Indiana Medicaid preferred drug list (PDL) program. Report 2 www.in.gov/legislative/igareports/agency/reports/FSSA19.pdf